Dental Materials
Volume 24, Issue 6 , Pages 765-772 , June 2008

Effect of mercury(II) on Nrf2, thioredoxin reductase-1 and thioredoxin-1 in human monocytes

  • John C. Wataha

      Affiliations

    • University of Washington, Seattle, WA 98195-7456, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1 206 543 5948; fax: +1 206 543 7783.
    • ,
  • Jill B. Lewis

      Affiliations

    • Medical College of Georgia, Augusta, GA 30912-1160, USA
    • ,
  • Veronica V. McCloud

      Affiliations

    • Medical College of Georgia, Augusta, GA 30912-1160, USA
    • ,
  • Melissa Shaw
    • ,
  • Yo Omata

      Affiliations

    • Hokkaido University, Sapporo, Japan
    • ,
  • Petra E. Lockwood

      Affiliations

    • Medical College of Georgia, Augusta, GA 30912-1160, USA
    • ,
  • Regina L.W. Messer

      Affiliations

    • Medical College of Georgia, Augusta, GA 30912-1160, USA
    • ,
  • Jason M. Hansen

      Affiliations

    • Emory University, Atlanta, GA, USA

Received 11 July 2007 ,Revised 30 August 2007 ,Accepted 4 September 2007.

References 

  1. Clarkson TW, Magos L. The toxicology of mercury and its chemical compounds. Crit Rev Toxicol. 2006;36:609–662
  2. Magos L, Clarkson TW. Overview of the clinical toxicity of mercury. Ann Clin Biochem. 2006;43:257–268
  3. Mackert JR, Berglund A. Mercury exposure from dental amalgam fillings: absorbed dose and the potential of adverse health effects. Crit Rev Oral Biol Med. 1997;8:410–436
  4. Hursh JB, Clarkson TW, Cherian MB, Vostal JJ, Vander MR. Clearance of mercury (Hg-197, Hg-203) vapor inhaled by human subjects. Arch Environ Health. 1976;31:302–309
  5. Berglund A. Estimation by a 24h study of the daily dose of intra-oral mercury vapor inhaled after released from dental amalgam. J Dent Res. 1990;1646–1651
  6. Sandborgh-Englund G, Elinder C-G, Johansson G, Lind B, Skare I, Ekstrand J. The absorption, blood levels, and excretion of mercury after a single dose of mercury vapor in humans. Toxicol Appl Pharmacol. 1998;150-146-53
  7. Sandborgh-Englund G, Elinder C-G, Langworth S, Schültz A, Ekstrand J. Mercury in biological fluids after amalgam removal. J Dent Res. 1998;77:615–624
  8. Clarkson TW, Magos L, Myers GJ. Human exposure to mercury: the three modern dilemmas. J Trace Elem Expt Med. 2003;16:321–343
  9. Clarkson TW, Magos M, Myers GJ. Current concepts—the toxicology of mercury-current exposures and clinical manifestations. New Eng J Med. 2003;1731–1737
  10. Goyer RA. Toxic effects of metals. In:  Klaassen CD,  Amdur MO,  Doull J editor. Casarett and Doull's toxicology. third ed.. New York: MacMillan; 1986;p. 582–635
  11. Whanger PD. Selenium and the brain: a review. Nut Neurobiol. 2002;4:81–97
  12. Messer RLW, Lockwood PE, Tseng WY, Edwards K, Shaw M, Caughman GB, et al. Mercury (II) alters mitochondrial activity of monocytes at sublethal doses via oxidative stress mechanisms. J Biomed Mater Res. 2005;75B:257–263
  13. Auger MJ, Ross JA. The biology of the macrophage. In:  Lewis CE,  McGee JO editor. The Macrophage. Oxfords: Oxford University Press; 1992;p. 3–74
  14. Wolf MB, Baynes JW. Cadmium and mercury cause an oxidative stress-induced endothelial cell dysfunction. Biometals. 2007;23:73–81
  15. Wataha JC, Lewis JB, Lockwood PE, Rakich DR. Effect of dental metal ions on glutathione levels in THP-1 human monocytes. J Oral Rehab. 2000;27:508–516
  16. Korashy HM, El-Kadi AOS. Transcriptional regulation of the NAD(P)H:quinone oxidoreductase 1 and glutathione-S-transferase YA genes by mercury, lead, and copper. Drug Metab Dispos. 2006;34:152–165
  17. Hirota K, Nakamura H, Masutani H, Yodoi J. Thioredoxin superfamily and thioredoxin-inducing agents. Ann NY Acad Sci. 2002;957:189–199
  18. Gromer S, Johansson L, Bauer H, Arscott LD, Rauch S, Ballou DP, et al. Active sites of thioredoxin reductases: why selenoproteins?. Proc Nat Acad Sci. 2003;100:12618–12623
  19. Jones DP, Watson WH. Oxidation of nuclear thioredoxin during oxidative stress. FEBS Lett. 2003;543:144–147
  20. Hansen J, Zhang H, Jones DP. Differential oxidation of thioredoxin-1, thioredoxin-2, and glutathione by metal ions. Free Rad Biol Med. 2006;40:138–145
  21. Brandt W, Wessjohann LA. The functional role of selenocysteine (Sec) in the catalysis mechanism of large thioredoxin reductases: proposition of a swapping catalytic triad including a Sec-His-Glu state. Chem Bio Chem. 2005;6:386–394
  22. Lee J-M, Meohlenkamp JD, Hanson JM, Johnson JA. Nrf2-dependent activation of the antioxidant responsive element by tert-butylhydroquinone is independent of oxidative stress in IMR-32 human neuroblastoma cells. Biochem Biophy Res Comm. 2001;280:286–292
  23. Kang KW, Lee SJ, Kim SG. Molecular mechanism of Nrf2 activation by oxidative stress. Antioxid Redox Signal. 2005;7:1664–1673
  24. Motohashi H, Yamamoto M. Nrf2-Keap1 defines a physiologically important stress response mechanism. Trends Mol Med. 2004;10:549–556
  25. Esposito F, Russo T, Cimino F. Generation of pro-oxidant conditions in intact cells to induce modification of cell cycle regulatory proteins. Meth Enzymol. 2002;352:258–268
  26. Mackert JR. The biocompatibility of dental amalgam. In:  Hardin JF editors. Clark's clinical dentistry. 1:Philadelphia: J.B. Lippincott; 1996;p. 1–15
  27. Omata Y, Lewis JB, Lockwood PE, Tseng WY, Messer RL, Bouillaguet S, et al. Gold-induced reactive oxygen species (ROS) do not mediate suppression of monocytic mitochondrial secretory function. Toxicol In Vitro. 2006;20:625–633
  28. Gringhuis SI, Breedveld FC, Verveij CL. Linker for activation of T cells, sensing redox imbalance. Meth Enzymol. 2002;352:248–257
  29. Sandalova T, Zhong L, Lindqvist Y, Holmgren A, Schneider G. Three-dimensional structure of a mammalian thioredoxin reductase: implications for mechanism and evolution of a selenocysteine-dependent enzyme. Proc Natl Acad Sci. 2001;98:9733–9738
  30. Zhong L, Arnér ESJ, Holmgren A. Structure and mechanism of mammalian thioredoxin reductase: the active site is a redox-active selenothiol/seleneylsulfide formed from the conserved cysteine-selenocysteine sequence. Proc Natl Acad Sci. 2000;97:5854–5859
  31. Gromer S, Urig S, Becker K. The thioredoxin system—from science to clinic. Med Res Rev. 2004;24:40–89
  32. Holmgren A, Bjornstedt M. Thioredoxin and thioredoxin reductase. Meth Enzymol. 1995;252:199–209
  33. Omata Y, Folan M, Shaw M, Messer RL, Lockwood PE, Hobbs DH, et al. Sublethal concentrations of diverse gold compounds inhibit mammalian cytosolic thioredoxin reductase (TrxR1). Toxicol In Vitro. 2006;20:882–890
  34. Heiss E, Gerhäuser C. Time-dependent modulation of thioredoxin reductase activity might contribute to sulophane-mediate inhibition of NF-κB binding to DNA. Antioxid Redox Signal. 2005;7:1601–1611
  35. Frankenberger M, Pforte A, Sternsdorf T, Passlick B, Baeurle PA, Ziegler-Heitbrock HWL. Constitutive nuclear NF-κB in cells of the monocyte lineage. Biochem J. 1994;304:87–94
  36. Lewis JB, Wataha JC, McCloud VV, Lockwood PE, Messer RLW, Tseng W-Y. Au(III), Pd(II), and Hg(II) alter NFκB signaling in THP1 monocytic cells. J Biomed Mater Res-A. 2005;74A:474–481
  37. Lee S-R, Bar-Noy S, Kwon J, Levine RL, Stadtman TC, Rhee SG. Mammalian thioredoxin reductase: oxidation of the C-terminal cysteine/selenocysteine active site forms a thioselenide, and replacement of selenium with sulfur markedly reduces catalytic activity. Proc Natl Acad Sci. 2000;97:2521–2526
  38. Zhong L, Holmgren A. Essential role of selenium in the catalytic activities of mammalian thioredoxin reductase revealed by characterization of recombinant enzymes with selenocysteine mutations. J Biol Chem. 2000;275:18121–18128
  39. Huang HC, Nguyen T, Pickett CB. Phosphorylation of Nrf2 at Ser-40 by protein kinase C regulated antioxidant response element-mediated transcription. J Biol Chem. 2002;277:42769–42774
  40. Rushworth SA, Chen SL, Mackman N, Ogborne RM, O’Connell MA. Lipopolysaccharide-induced heme oxygenase-1 expression in human monocytic cells is mediated via Nrf2 and protein kinase C. J Immunol. 2005;175:4408–4415
  41. Nguyen T, Sherratt PJ, Huang H-C, Yang CS, Pickett CB. Increased protein stability as a mechanism that enhances Nrf2-mediated transcriptional activation of the antioxidant response element. J Biol Chem. 2003;278:4535–4541
  42. Lee JM, Clakins MJ, Chan K, Kan YW, Johnson JA. Identification of the NF-E2-related factor-2-dependent genes conferring protection against oxidative stress in primary cortical atrocities using oligonucleotide microarray analysis. J Biol Chem. 2003;278:12039–12138
  43. Tanudjii M, Hevi S, Chuck SL. The nonclassic secretion of thioredoxin is not sensitive to redox state. Am J Physiol Cell Physiol. 2003;284:C1272–C1279
  44. Sugimoto M, Inoue T, Takeshita K, Hakmua H, Yodoi J. Effects of a new anti-rheumatic drug KE-28 and its active metabolite KE-758 on secretion of thioredoxin and on the level of intracellular gluathione in human monocytes and T cells. Mol Immunol. 2001;38:793–799

PII: S0109-5641(07)00220-5

doi: 10.1016/j.dental.2007.09.002

Dental Materials
Volume 24, Issue 6 , Pages 765-772 , June 2008

Article Tools

* Image Usage & Resolution